AXGN
Axogen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 7
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Gap Up
High Cash/net Profit Ratio
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AXGN
Axogen, Inc.
A global leader in developing innovative surgical solutions for peripheral nerve injuries
Healthcare Equipment and Supplies
--
08/09/2013
NASDAQ Stock Exchange
451
12-31
Common stock
13631 Progress Blvd.
, Suite 400 Alachua
, FL 32615
--
Founded in 1977 in Minnesota, Axogen, Inc., is a leading company in regenerative pharmaceuticals, dedicated to the development and marketing of peripheral nerve healing drugs. Peripheral nerves transmit signals for people to perform movement and sensation, and damage to peripheral nerves can cause the loss of functional sensation.
Earnings Call
Q1/2025
Estimate EPS0.02
Actual EPS-0.02
Estimate Revenue48.35M
Actual Revenue48.56M
Axogen's Q1 2025: Navigating Contradictions in Growth Strategies and Margin Expectations
May 19,2025 12:53
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.06
Actual EPS0.12
Estimate Revenue52.61M
Actual Revenue56.66M
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies
Aug 05,2025 01:26
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AXGN has released its 2025 Q3 earnings. EPS was reported at 0.12, versus the expected 0.07, beating expectations. The chart below visualizes how AXGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AXGN has released its 2025 Q3 earnings report, with revenue of 60.08M, reflecting a YoY change of 23.51%, and net profit of 708.00K, showing a YoY change of 138.11%. The Sankey diagram below clearly presents AXGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
